Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel SyndromeOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated the fecal microbiome of patients with irritable bowel syndrome (IBS) to identify signatures specific to IBS subtypes. Researchers analyzed 273 fecal samples using 16S rRNA sequencing, generating more than 20 million sequences. They examined microbial diversity and the relative abundance of specific bacterial and archaeal groups, including butyrate producers and methane producers, and correlated taxa with symptoms like flatulence and abdominal pain.
Who was studied?
The cohort consisted of 113 patients with IBS and 66 healthy controls, for a total of 179 participants. A subset of these participants provided two fecal samples one month apart, allowing some assessment of stability over time. The abstract does not specify age, sex, or geographic location of the cohort.
What were the most important findings?
IBS patients had significantly lower microbial diversity, which was associated with a lower relative abundance of butyrate-producing bacteria (P = 0.002; q < 0.06), particularly in those with IBS-D and IBS-M subtypes. Untreated IBS patients also had a lower abundance of Methanobacteria compared to healthy controls (P = 0.005; q = 0.05). Several bacterial taxa were significantly correlated with sensations of flatulence and abdominal pain (P < 0.05).
What are the greatest implications of this study?
The findings suggest that reduced butyrate producers may impair intestinal barrier function in IBS-D and IBS-M patients, since butyrate is known to support gut barrier integrity. Lower methane-producing microorganisms may reduce hydrogen disposal in the colon, potentially explaining the excess abdominal gas reported in IBS. Together these microbial signatures point toward specific, subtype-linked mechanisms that could inform future diagnostic or therapeutic approaches for IBS.